LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.

    Phillips, Elizabeth H / Devereux, Stephen / Radford, John / Mir, Naheed / Adedayo, Toyin / Clifton-Hadley, Laura / Johnson, Rod

    Leukemia & lymphoma

    2019  Volume 60, Issue 9, Page(s) 2291–2294

    MeSH term(s) Adult ; Aged ; Alemtuzumab/administration & dosage ; Alemtuzumab/adverse effects ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Humans ; Incidence ; Lymphoma, T-Cell/drug therapy ; Lymphoma, T-Cell/immunology ; Lymphoma, T-Cell/mortality ; Maximum Tolerated Dose ; Middle Aged ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Progression-Free Survival ; Survival Rate ; Vincristine/administration & dosage ; Vincristine/adverse effects ; Virus Activation/drug effects ; Virus Activation/immunology ; Virus Diseases/chemically induced ; Virus Diseases/epidemiology ; Virus Diseases/immunology
    Chemical Substances Antineoplastic Agents, Immunological ; Alemtuzumab (3A189DH42V) ; Vincristine (5J49Q6B70F) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P) ; Prednisone (VB0R961HZT)
    Language English
    Publishing date 2019-02-18
    Publishing country United States
    Document type Clinical Trial, Phase I ; Comparative Study ; Letter ; Multicenter Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2019.1576870
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.

    Chan, Wei Yee / Counsell, Nicholas / de Tute, Ruth / De-Silva, Dunnya / Phillips, Elizabeth H / Cavenagh, Jamie / Adedayo, Toyin / Braganca, Nivette / Roddie, Claire / Streetly, Matthew / Schey, Stephen / Koh, Mickey B C / Crowe, Josephine / Morris, Treen C / Cook, Gordon / Clifton-Hadley, Laura / Rabin, Neil / Owen, Roger G / Popat, Rakesh /
    Yong, Kwee L

    British journal of haematology

    2021  Volume 196, Issue 4, Page(s) e33–e37

    MeSH term(s) Adult ; Aged ; Bortezomib/pharmacology ; Bortezomib/therapeutic use ; Dexamethasone/pharmacology ; Dexamethasone/therapeutic use ; Doxorubicin/pharmacology ; Doxorubicin/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Neoplasm Recurrence, Local ; Treatment Outcome
    Chemical Substances Bortezomib (69G8BD63PP) ; Dexamethasone (7S5I7G3JQL) ; Doxorubicin (80168379AG)
    Language English
    Publishing date 2021-10-11
    Publishing country England
    Document type Clinical Trial, Phase II ; Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.17903
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.182: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.

    Popat, Rakesh / Counsell, Nicholas / de Tute, Ruth / De-Silva, Dunnya / Phillips, Elizabeth H / Cavenagh, Jamie D / Adedayo, Toyin / Braganca, Nivette / Roddie, Claire / Streetly, Matthew / Schey, Steve / Koh, Mickey B C / Crowe, Josephine / Morris, Treen C / Cook, Gordon / Smith, Paul / Clifton-Hadley, Laura / Rabin, Neil / Owen, Roger /
    Yong, Kwee

    British journal of haematology

    2021  Volume 193, Issue 3, Page(s) e19–e22

    MeSH term(s) Adult ; Aged ; Autografts ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/therapy ; Stem Cell Transplantation ; Survival Rate
    Language English
    Publishing date 2021-03-14
    Publishing country England
    Document type Clinical Trial, Phase II ; Letter ; Multicenter Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.17391
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.182: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.

    Rule, Simon / Cook, Gordon / Russell, Nigel H / Hunter, Ann / Robinson, Stephen / Morley, Nick / Sureda, Anna / Patrick, Pip / Clifton-Hadley, Laura / Adedayo, Toyin / Kirkwood, Amy / Peggs, Karl S

    British journal of haematology

    2018  Volume 184, Issue 6, Page(s) 999–1005

    Abstract: Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin lymphoma that remains incurable for the majority of patients. Allogeneic stem cell transplantation (alloSCT) produces long-term disease-free remissions for around 30-40% patients, however it ...

    Abstract Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin lymphoma that remains incurable for the majority of patients. Allogeneic stem cell transplantation (alloSCT) produces long-term disease-free remissions for around 30-40% patients, however it is reserved for the treatment of relapsed disease. This study examined the use of front line transplantation for young patients in an attempt to improve outcomes. Twenty-five patients received an alloSCT using BEAM [BCNU (carmustine), etoposide, cytarabine, melphalan)-Campath conditioning following permissive induction therapy from both related and unrelated donors. This was a multi-centre prospective trial. Twenty-four of 25 patients engrafted with no non-relapse mortality events by day 100. With a median follow-up of 60·5 months, there have been six deaths (3 from MCL). The progression-free survival (PFS) and overall survival were 68% and 80% at 2 years and 56% and 76% at 5 years. PFS was very similar for both sibling and unrelated transplants and there was no difference in PFS between patients with respect to remission status prior to transplantation. Nine (38%) patients experienced acute graft-versus-host disease (GVHD) and 14 (58%) experienced chronic GVHD, of which 8 were extensive. Front line alloSCT is feasible but should only be considered for patients at high risk of early progression following conventional therapy.
    MeSH term(s) Adult ; Aged ; Female ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Lymphoma, Mantle-Cell/pathology ; Lymphoma, Mantle-Cell/therapy ; Lymphoma, Non-Hodgkin/pathology ; Lymphoma, Non-Hodgkin/therapy ; Male ; Middle Aged ; Transplantation Conditioning/methods ; Transplantation, Homologous/methods
    Language English
    Publishing date 2018-12-17
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.15723
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.182: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study.

    Phillips, Elizabeth H / Nash, Stephen / Adedayo, Toyin / Whelan, Carol J / Fontana, Marianna / Mahmood, Shameem / Lachmann, Helen J / Gillmore, Julian D / Smith, Paul / Clifton-Hadley, Laura / Hawkins, Philip N / Wechalekar, Ashutosh D

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

    2017  Volume 24, Issue 4, Page(s) 242–244

    MeSH term(s) Aged ; Bortezomib/administration & dosage ; Cardiomyopathies/drug therapy ; Cardiomyopathies/epidemiology ; Cardiomyopathies/pathology ; Cyclophosphamide/administration & dosage ; Dexamethasone/administration & dosage ; Doxorubicin/administration & dosage ; Drug Combinations ; Female ; Humans ; Immunoglobulin Light-chain Amyloidosis/drug therapy ; Immunoglobulin Light-chain Amyloidosis/epidemiology ; Immunoglobulin Light-chain Amyloidosis/pathology ; Male ; Middle Aged ; Survival Analysis
    Chemical Substances Drug Combinations ; Bortezomib (69G8BD63PP) ; Dexamethasone (7S5I7G3JQL) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P)
    Language English
    Publishing date 2017-10-06
    Publishing country England
    Document type Clinical Trial, Phase II ; Letter
    ZDB-ID 1205246-2
    ISSN 1744-2818 ; 1350-6129
    ISSN (online) 1744-2818
    ISSN 1350-6129
    DOI 10.1080/13506129.2017.1385453
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4114: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.

    Chapman, Michael A / Sive, Jonathan / Ambrose, John / Roddie, Claire / Counsell, Nicholas / Lach, Anna / Abbasian, Mahnaz / Popat, Rakesh / Cavenagh, Jamie D / Oakervee, Heather / Streetly, Matthew J / Schey, Stephen / Koh, Mickey / Willis, Fenella / Virchis, Andres E / Crowe, Josephine / Quinn, Michael F / Cook, Gordon / Crawley, Charles R /
    Pratt, Guy / Cook, Mark / Braganza, Nivette / Adedayo, Toyin / Smith, Paul / Clifton-Hadley, Laura / Owen, Roger G / Sonneveld, Pieter / Keats, Jonathan J / Herrero, Javier / Yong, Kwee

    Blood

    2018  Volume 132, Issue 20, Page(s) 2154–2165

    Abstract: Improving outcomes in multiple myeloma will involve not only development of new therapies but also better use of existing treatments. We performed RNA sequencing on samples from newly diagnosed patients enrolled in the phase 2 PADIMAC (Bortezomib, ... ...

    Abstract Improving outcomes in multiple myeloma will involve not only development of new therapies but also better use of existing treatments. We performed RNA sequencing on samples from newly diagnosed patients enrolled in the phase 2 PADIMAC (Bortezomib, Adriamycin, and Dexamethasone Therapy for Previously Untreated Patients with Multiple Myeloma: Impact of Minimal Residual Disease in Patients with Deferred ASCT) study. Using synthetic annealing and the large margin nearest neighbor algorithm, we developed and trained a 7-gene signature to predict treatment outcome. We tested the signature in independent cohorts treated with bortezomib- and lenalidomide-based therapies. The signature was capable of distinguishing which patients would respond better to which regimen. In the CoMMpass data set, patients who were treated correctly according to the signature had a better progression-free survival (median, 20.1 months vs not reached; hazard ratio [HR], 0.40; confidence interval [CI], 0.23-0.72;
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Doxorubicin/therapeutic use ; Humans ; Kaplan-Meier Estimate ; Lenalidomide/therapeutic use ; Machine Learning ; Multiple Myeloma/drug therapy ; Multiple Myeloma/genetics ; Mutation ; Proportional Hazards Models ; Sequence Analysis, RNA ; Transcriptome ; Treatment Outcome ; United States
    Chemical Substances Antineoplastic Agents ; Bortezomib (69G8BD63PP) ; Dexamethasone (7S5I7G3JQL) ; Doxorubicin (80168379AG) ; Lenalidomide (F0P408N6V4)
    Language English
    Publishing date 2018-09-04
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2018-05-849893
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top